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Background: Hepatitis A virus (HAV) has a worldwide distribution, although this distribu-
tion tends to be uneven among geographical regions and population groups. The preva-
lence of anti-HAV antibodies in the general population varies widely among countries. In 
europe, the seroprevalence of HAV is reported to range from 32% to 88%.
Objectives: The aim of this study was to determine the seroprevalence of HAV among the 
general Croatian population.
Materials and Methods: During a 2-year period (2008–2009), a total of 791 serum samples 
were tested for the presence of anti-HAV total (IgM+IgG) and anti-HAV IgM antibodies 
using an automated enzyme-linked fluorescent assay (Mini Vidas; bioMérieux, Marcy 
l’etoile, France).
Results: The overall anti-HAV seroprevalence was 41.6%. The observed difference in the se-
roprevalence rates among male and female patients was not statistically significant (44% 
vs. 39.6%, P = 0.218). A marked increase in anti-HAV seropositivity with age was observed (P 
< 0.001). The seroprevalence did not differ significantly between participants residing in 
rural regions (45.3%) and those residing in urban regions (40.6%, P = 0.292). 
Conclusions: our results corroborate those of seroprevalence studies in other developed 
countries. More than half of the Croatian population (59.4%) is susceptible to HAV infec-
tion. older age is an important predictor for being anti-HAV positive.
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 Implication for health policy/practice/research/medical education:
HAV represents a significant cause of morbidity throughout the world. The distribution varies widely among geographical regions and popu-
lation groups. Information regarding the status of HAV immunity is crucial for the control of this infection as well as for immunization.
Copyright  c 2011 Kowsar M. P. Co. All rights reserved. 
* Corresponding author: Tatjana Vilibic-Cavlek, Department of Virology, 
Croatian  national  Institute  of  public  Health,  Rockefellerova  12,  Zagreb, 
Croatia. Tel: + 38-514863238, Fax: + 38-514683017,
E-mail: tatjana.vilibic-cavlek@hzjz.hr
DoI: 10.5812/kowsar.1735143X.756
Copyright  c2011 Kowsar M.P.Co.  All rights reserved.
1. Background
Hepatitis A virus (HAV) is a significant cause of morbid-
ity in many parts of the world. HAV infections account 
for 1.5 million cases of hepatitis each year (1). It has a 
global, although uneven distribution among geographi-
cal regions and population groups. The primary mode of 
HAV transmission is the fecal-oral route, most frequently 
person-to-person, or by ingestion of contaminated food 
or water (2). The exact prevalence, however, is difficult 
to estimate because of the high proportion of asymp-
tomatic and anicteric infections. Seroepidemiological 
studies have shown that the prevalence of anti-HAV an-
tibodies in the general population varies widely among 
countries, from as low as 13% in the Scandinavian coun-
tries to nearly 100% in areas of developing countries, 
such as parts of Africa, Asia, and South America (3). In 
these developing countries, exposure to HAV before the 
age of 9 is almost universal (4). In developed countries, 
transmission shifts to older age groups, and seropreva-
lence increases during adulthood. In Europe, the serop-
revalence of HAV is reported to range from 32% (in Italy 
and Ukraine) to 88% (in Kosovo) (5-12). There are, however, 
very few published studies on the seroprevalence of HAV 998 Seroprevalence of HAV Antibodies in Croatia Vilibic-Cavlek T et al.
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in Croatia, and these have been limited to specific popu-
lation groups (13, 14). 
2. Objectives
The aim of this study was to determine the seropreva-
lence of HAV among the Croatian general population.
3. Materials and Methods
During a 2-year period (2008–2009), a total of 791 serum 
samples were tested for the presence of anti-HAV total 
(IgM+IgG) and anti-HAV IgM antibodies at the Labora-
tory for serologic diagnosis, Croatian national Institute 
of Public Health and Istria County Institute of Public 
Health. Serologic tests were performed using an auto-
mated enzyme-linked fluorescent assay (Mini Vidas; bio-
Mérieux, Marcy l’etoile, France). The manufacturer states 
a diagnostic sensitivity of 99.4% and specificity of 100%. 
There  were  352  (44.5%)  males  and  439  (55.5%)  females 
aged from 2 to 87 years residing in different cities in four 
of the 20 Croatian counties (Figure 1). Serum samples 
were obtained from hospitalized patients: preoperative 
check-up  (cardiac  surgery,  renal  transplant  program) 
and non-hospitalized patients coming for routine test-
ing (physical examination, needle stick injury, patient 
contacts, lymphatic disorders, antenatal screening, and 
couples undergoing medically assisted reproduction) 
with no symptoms of acute hepatitis. The only exclusion 
criteria were chronic liver diseases. Since no background 
seroprevalence data was available as a base to calculate 
sample  size,  we  took  the  conservative  estimate  of  p = 
0.05 and a margin error e = 0.05 (tolerable width of 95% 
confidence interval of 10%), which gave us a minimum 
required sample size of 384 examinees. The formula used 
to calculate the required sample size was n = zα2p(1-p)/E2.
3.1. Statistical Analysis
A comparison of categorical variables between groups 
was made using Fisher’s exact test. Statistical analyses 
were performed using STATA/IC 11.1 for Windows (Stata-
Corp LP, USA). P < 0.05 was considered as statistically sig-
nificant.
4. Results
of 791 analyzed serum samples, 329 (41.6%) were posi-
tive  for  anti-HAV  total  antibodies.  The  seroprevalence 
rate was 44% (155/352) among males and 39.6% (174/439) 
among females, with no significant difference (P = 0.218). 
Anti-HAV  positivity  was  low  in  participants  under  30 
years of age, ranging from 4.8% to 9.1%. A marked increase 
in seropositivity with age was observed beginning with 
the 30- to 39-year age group. The seroprevalence progres-
sively increased from 22.3% in 30 to 39 year olds to 93.7% 
in participants older than 60 years (P < 0.001). The sero-
positivity rate in participants residing in rural regions 
was 45.3% (77/170), compared to 40.6% (252/621) in partici-
pants residing in urban regions. This difference was not 
statistically significant (P = 0.292) (Table 1). no acute HAV 
infections were detected during the testing period.
Tested, No. (%) Anti-HAV, No. (%) 95% CI P value
Gender 0.218
Male
Female
352 (44.5)
439 (55.5)
155 (44.0)
174 (39.6)
38.8–49.4
35–44.4
Age group, y < 0.001
< 9
10–19
20–29
30–39
40–49
50–59
≥ 60
11 (1.4)
42 (5.3)
147 (18.6)
202 (25.6)
132 (16.7)
146 (18.4)
111 (14.0)
1 (9.1)
2 (4.8)
13 (8.8)
45 (22.3)
58 (43.9) 
106 (72.6)
104 (93.7)
0.2–41.3
0.6–16.2
4.8–14.6
16.7–28.6
35.3–52.8
64.6–79.7
87.4–97.4
Place of residence 0.292
Urban
Rural
621 (78.5)
170 (21.5)
252 (40.6)
77 (45.3)
36.7–44.6
37.7–53.1
 Table 1. prevalence of Anti-HAV Antibodies in the Croatian population
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5. Discussion
This study has shown that HAV seroprevalence in Croa-
tia (41.6%) is comparable to that in Germany (46.5%) (15) 
and Luxembourg (42%) (10). Some countries, such as the 
netherlands, the Czech Republic, Spain, and Kosovo, have 
higher seroprevalence rates (57%, 61.6%, 68.2%, and 88.6%, 
respectively) (7, 8, 11), whereas Italy, Ukraine, and england 
and Wales have reported lower seroprevalence rates (32%, 
31.9%, and 30.7%, respectively) (5, 9, 16). HAV seropositiv-
ity was strongly age-dependent, which is similar to the 
findings of other published studies (5, 9-11, 17). The results 
of this study indicate that the majority of children and 
young adults are susceptible to HAV (90% of participants 
under 30 years of age and 78% of 30- to 39-year-old partici-
pants). In contrast, the majority of people older than 50 
have documented immunity to HAV. In comparison with 
a previous study conducted in Croatia (14), we show a de-
crease in the seroprevalence rate among children under 
15 years of age living in rural areas from 18.7% two decades 
ago to 5.6% during the period 2008–2009. Improvements 
in hygiene and sanitary conditions are determining fac-
tors  for  HAV  prevalence  in  the  community,  and  these 
probably had an impact on the declining prevalence dur-
ing 2008–2009, compared to 1989 (18). In the past, older 
people had a greater probability of becoming infected 
due to poorer hygiene and sanitation (8). Another Croa-
tian study, conducted in 2006 among 360 men who had 
sex with men aged 18–69, showed a seroprevalence rate 
of 14.2% (13). Men are generally at greater risk from hepa-
titis A virus infection than are women (7, 19). We found 
no significant difference in HAV seropositivity between 
males and females (44% and 39.6%, respectively). In con-
trast, a Thai study showed a significantly higher anti-HAV 
seroprevalence rate in females compared to males (20). 
Furthermore, in several studies, higher HAV seropreva-
lences have been observed in persons living in rural ar-
eas (5, 11). This study, however, found no difference in HAV 
seroprevalence between participants who reside in rural 
areas and those residing in urban areas (45.3% vs. 40.6%).
In conclusion, the present data corroborate seropreva-
lence studies in other developed countries. More than 
half of the Croatian population (59.4%) is susceptible to 
HAV infection. older age is an important predictor for be-
ing anti-HAV positive. Further, the prevalence of anti-HAV 
antibodies in children has decreased in recent years. In-
formation regarding the status of HAV immunity is cru-
cial for the control of this viral infection, as well as for 
immunization.
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